PanTher Therapeutics Drug Delivery Device Patent (US12605356B2)
Summary
The USPTO granted patent US12605356B2 to PanTher Therapeutics, Inc. covering implantable and biodegradable drug delivery devices for direct delivery of active pharmaceutical ingredients to pancreatic tumor tissue. The devices feature a two-layer design where one layer contains the API with a biodegradable polymer and a second layer prevents API release away from the target tissue. The patent names Laura Indolfi and Margaret Lashof-Sullivan as inventors.
What changed
The USPTO issued patent US12605356B2 to PanTher Therapeutics, Inc. covering biodegradable multi-layer drug delivery devices capable of targeted API delivery to pancreatic tumor tissue. The patent includes 16 claims and covers devices where one layer containing an active pharmaceutical ingredient degrades to release the drug toward the target tissue while a second slower-degrading layer prevents off-target release.
Manufacturers and developers of implantable drug delivery systems, particularly those targeting oncology applications, should monitor this intellectual property landscape. PanTher's patent position in targeted pancreatic cancer drug delivery may affect freedom-to-operate considerations for competing delivery technologies in this space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating pancreatic cancer
Grant US12605356B2 Kind: B2 Apr 21, 2026
Assignee
PanTher Therapeutics, Inc.
Inventors
Laura Indolfi, Margaret Lashof-Sullivan
Abstract
Provided are implantable and biodegradable drug delivery devices capable of delivering an active pharmaceutical ingredient (API) directly to a target pancreatic tumor tissue. The drug delivery devices can include at least two layers. One of the layers can include the API and a biodegradable polymer and a second layer can include another biodegradable polymer that degrades slower than the first biodegradable polymer. When the device is placed directly on the target tissue, the API layer can degrade thereby releasing the API towards the target tissue while the non-API layer can prevent the API from being released away from the target tissue onto non-target tissue.
CPC Classifications
A61K 31/337 A61K 9/24 A61P 35/00
Filing Date
2023-10-26
Application No.
18495476
Claims
16
Named provisions
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.